RxDoctor Payments Data

Katherine Cox, APRN

Family · Barboursville, WVNPI 1952858011

Payments from drug & device makers

$6,452in general payments, 2019–2025

Across 421 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$683
  • Biohaven Pharmaceuticals, Inc.$428
  • GSK$378
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$334
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$6,42099%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,452 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$41,914
Medicare patients
170
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$98,638
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$39,280
EliquisApixaban33$30,824
TradjentaLinagliptin32$30,369
JanuviaSitagliptin Phosphate20$26,250
JardianceEmpagliflozin16$24,275
MounjaroTirzepatide11$11,298
VascepaIcosapent Ethyl24$10,948
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$10,840
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,250
Novolog FlexpenInsulin Aspart13$4,977
Duloxetine Hcl107$3,951
Levothyroxine Sodium288$2,423
Omeprazole237$2,137
Albuterol Sulfate HfaAlbuterol Sulfate91$2,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,002$98,63883 claims
Boehringer IngelheimTradjenta, Jardiance$272$54,64448 claims
GSKTrelegy Ellipta$378$39,28034 claims
PfizerEliquis$683$30,82433 claims
MerckJanuvia$197$26,25020 claims
Lilly USA, LLCMounjaro$79$11,29811 claims
AstraZenecaBreztri Aerosphere$228$8,25013 claims
AbbVieSynthroid$1,174$62321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.

Other family in Barboursville

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →